Sera proteomic biomarker profiling in HIV-1 infected subjects with cognitive impairment

Proteomics - Clinical Applications

Volumn 2, Issue 10-11, 2008, Pages 1498-1507

  Rozek, Wojciech ^a,b   Horning, Jayme ^c   Anderson, James ^c   Ciborowski, Pawel ^a,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NATIONAL VETERINARY RESEARCH INSTITUTE   (Poland)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

2 D DIGE; Biomarker; Cognitive impairment; HIV 1

Indexed keywords

AFAMIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; CERULOPLASMIN; COMPLEMENT COMPONENT C3; FIBRINOGEN; HAPTOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; OROSOMUCOID; PLASMA PROTEIN; SERUM ALBUMIN; TRANSFERRIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CHEMICAL LABELING; CHEMOLUMINESCENCE; COGNITIVE DEFECT; CONTROLLED STUDY; ELECTROPHORESIS; GENE EXPRESSION PROFILING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PILOT STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 64749112915     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200780114     Document Type: Article

References (55)

1. Bottiggi, K. A., Chang, J. J., Schmitt, F. A., Avison, M. J. et al., The HIV Dementia Scale: Predictive power in mild dementia and HAART. J. Neurol. Sci. 2007, 260, 11-15.
2. Ances, B. M., Ellis, R. J., Dementia and neurocognitive disorders due to HIV-1 infection. Semin. Neurol. 2007, 27, 86-92.
3. Navia, B. A., Price, R. W., Clinical and biological features of the AIDS dementia complex, in: Gendelman, H. E., Lipton, S. A., Epstein, L., Swindells, S. (Eds.), The Neurology of AIDS. Chapman and Hall, New York 1998, pp. 229-240.
4. Wilkie, F. L., Goodkin, K., Khamis, I., van Zuilen, M. H. et al., Cognitive functioning in younger and older HIV-1-infected adults. J. Acquir. Immune. Defic. Syndr. 2003, 33, S93-S105.
5. Kaul, M., Garden, G. A., Lipton, S. A., Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 2001, 410, 988-994.
6. Nath, A., Sacktor, N., Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr. Opin. Neurol. 2006, 19, 358-361.
7. Nath, A., Schiess, N., Venkatesan, A., Rumbaugh, J. et al., Evolution of HIV dementia with HIV infection. Int. Rev. Psychiatry 2008, 20, 25-31.
8. Wojna, V., Skolasky, R. L., Hechavarria, R., Mayo, R. et al., Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J. Neurovirol. 2006, 12, 356-364.
9. McArthur, J. C., Haughey, N., Gartner, S., Conant, K. et al., Human immunodeficiency virus-associated dementia: An evolving disease. J. Neurovirol. 2003, 9, 205-221.
10. McArthur, J. C., Brew, B. J., Nath, A., Neurological complications of HIV infection. Lancet Neurol. 2005, 4, 543-555.
11. McArthur, J. C., Sacktor, N., Selnes, O., Human immunodeficiency virus-associated dementia. Semin. Neurol. 1999, 19, 129-150.
12. Ghafouri, M., Amini, S., Khalili, K., Sawaya, B. E., HIV-1 associated dementia: Symptoms and causes. Retrovirology 2006, 3, 28.
13. Price, R. W., Epstein, L. G., Becker, J. T., Cinque, P. et al., Biomarkers of HIV-1 CNS infection and injury. Neurology 2007, 69, 1781-1788.
14. Bandaru, V. V., McArthur, J. C., Sacktor, N., Cutler, R. G. et al., Associative and predictive biomarkers of dementia in HIV-1-infected patients. Neurology 2007, 68, 1481-1487.
15. Gisslen, M., Hagberg, L., Brew, B. J., Cinque, P. et al., Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J. Infect. Dis. 2007, 195, 1774-1778.
16. Sui, Z., Sniderhan, L. F., Schifitto, G., Phipps, R. P. et al., Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: implications in HIV type 1 dementia. J. Immunol. 2007, 178, 3226-3236.
17. Dunfee, R. L., Thomas, E. R., Gorry, P. R., Wang, J. et al., The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 15160-15165.
18. Jurado, A., Rahimi-Moghaddam, P., Bar-Jurado, S., Richardson, J. S. et al., Genetic markers on HIV-1 gp120 C2-V3 region associated with the expression or absence of cognitivemotor complex in HIV/AIDS. J. NeuroAIDS 1999, 2, 15-28.
19. Rozek, W., Ricardo-Dukelow, M., Holloway, S., Wojna, V. et al., Cerebrospinal fluid proteomics profiling of HIV-1-infected patients with or at risk for cognitive impairments. J. Proteome Res. 2007, 6, 4189-4199.
20. Laspiur, J. P., Anderson, E. R., Ciborowski, P., Wojna, V. et al., CSF proteomic fingerprints for HIV-associated cognitive impairment. J. Neuroimmunol. 2007.
21. Simonsen, A. H., McGuire, J., Hansson, O., Zetterberg, H. et al., Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch. Neurol. 2007, 64, 366-370.
22. Simonsen, A. H., McGuire, J., Podust, V. N., Davies, H. et al., Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Neurobiol. Aging 2007.
23. Huang, J. T., Leweke, F. M., Oxley, D., Wang, L. et al., Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med. 2006, 3, e428.
24. Fonteh, A. N., Harrington, R. J., Huhmer, A. F., Biringer, R. G. et al., Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods. Dis. Markers 2006, 22, 39-64.
25. Yuan, X., Desiderio, D. M., Proteomics analysis of human cerebrospinal fluid. J. Chromatogr, B. Analyt. Technol. Biomed. Life Sci. 2005, 815, 179-189.
26. Yuan, X., Desiderio, D. M., Proteomics analysis of phosphotyrosyl-proteins in human lumbar cerebrospinal fluid. J. Proteome Res. 2003, 2, 476-487.
27. Khwaja, F.W., Nolen, J. D., Mendrinos, S. E., Lewis, M. M. et al., Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers. Proteomics 2006, 6, 6277-6287.
28. Thompson, E. J., Proteins of the Cerebrospinal Fluid: Analysis & Interpretation in the Diagnosis and Treatment of Neurological Disease, Elsevier Academic Press, San Diego, CA and Oxford, UK, 2005.
29. Ogata, Y., Charlesworth, M. C., Muddiman, D. C., Evaluation of protein depletion methods for the analysis of total-, phospho- and glycoproteins in lumbar cerebrospinal fluid. J. Proteome Res. 2005, 4, 837-845.
30. Wittke, S., Mischak, H., Walden, M., Kolch, W. et al., Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: Towards new diagnostic and therapeutic approaches. Electrophoresis 2005, 26, 1476-1487.
31. Terry, D. E., Desiderio, D. M., Between-gel reproducibility of the human cerebrospinal fluid proteome. Proteomics 2003, 3, 1962-1979.
32. Carrette, O., Demalte, I., Scherl, A., Yalkinoglu, O. et al., A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 2003, 3, 1486-1494.
33. Puchades, M., Hansson, S. F., Nilsson, C. L., Andreasen, N. et al., Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res. Mol. Brain Res. 2003, 118, 140-146.
34. Ruetschi, U., Zetterberg, H., Podust, V. N., Gottfries, J. et al., Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp. Neurol. 2005, 196, 273-281.
35. Jiang, L., Lindpaintner, K., Li, H. F., Gu, N. F. et al., Proteomic analysis of the cerebrospinal fluid of patients with schizophrenia. Amino Acids 2003, 25, 49-57.
36. Hammack, B. N., Fung, K. Y., Hunsucker, S. W., Duncan, M. W. et al., Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult. Scler. 2004, 10, 245-260.
37. Teunissen, C. E., Dijkstra, C., Polman, C., Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol. 2005, 4, 32-41.
38. Hsu, H. S., Chen, T. P., Hung, C. H., Wen, C. K. et al., Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer 2007, 9, 2019-2026.
39. Brouard, S., Mansfield, E., Braud, C., Li, L. et al., Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc. Natl. Acad. Sci. USA 2007 104, 15448-15453.
40. Steinerman, J. R., Honig, L. S., Laboratory biomarkers in Alzheimer's disease. Curr. Neurol. Neurosci. Rep. 2007, 7, 381-387.
41. Vanacore, N., Galeotti, F., Maggini, M., Raschetti, R., Biomarkers in dementia. Arch. Neurol. 2007, 64, 1356.
42. Antinori, A., Arendt, G., Becker, J. T., Brew, B. J. et al., Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007, 69, 1789-1799.
43. Ciborowski, P., Enose, Y., Mack, A., Fladseth, M., Gendelman, H. E., Diminished matrix metalloproteinase 9 secretion in human immunodeficiency virus-infected mononuclear phagocytes: Modulation of innate immunity and implications for neurological disease. J. Neuroimmunol 2004, 157, 11-16.
44. Nagalla, S. R., Canick, J. A., Jacob, T., Schneider, K. A. et al., Proteomic analysis of maternal serum in down syndrome: identification of novel protein biomarkers. J. Proteome Res. 2007, 6, 1245-1257.
45. Corzett, T. H., Fodor, I. K., Choi, M.W., Walsworth, V. L. et al., Statistical analysis of the experimental variation in the proteomic characterization of human plasma by two-dimensional difference gel electrophoresis. J. Proteome Res. 2006, 5, 2611-2619.
46. Lichenstein, H. S., Lyons, D. E., Wurfel, M. M., Johnson, D. A. et al., Afamin is a new member of the albumin, alpha-fetoprotein, and vitamin D-binding protein gene family. J. Biol. Chem. 1994, 269, 18149-18154.
47. Speeckaert, M., Huang, G., Delanghe, J. R., Taes, Y. E., Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin. Chim. Acta 2006, 372, 33-42.
48. Heiser, M., Hutter-Paier, B., Jerkovic, L., Pfragner, R. et al., Vitamin E binding protein afamin protects neuronal cells in vitro. J. Neural Transm. Suppl. 2002, 220, 337-345.
49. Jerkovic, L., Voegele, A. F., Chwatal, S., Kronenberg, F. et al., Afamin is a novel human vitamin E-binding glycoprotein characterization and in vitro expression. J. Proteome Res. 2005, 4, 889-899.
50. Loeffler, D. A., LeWitt, P. A., Juneau, P. L., Sima, A. A. et al., Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Brain Res. 1996, 738, 265-274.
51. Das, D., Tapryal, N., Goswami, S. K., Fox, P. L., Mukhopadhyay, C. K., Regulation of ceruloplasmin in human hepatic cells by redox active copper: Identification of a novel AP-1 site in the ceruloplasmin gene. Biochem. J. 2007, 402, 135-141.
52. Waggoner, D. J., Bartnikas, T. B., Gitlin, J. D., The role of copper in neurodegenerative disease. Neurobiol. Dis. 1999, 6, 221-230.
53. Klevay, L. M., Alzheimer's disease as copper deficiency. Med. Hypotheses 2008, 70, 802-807.
54. Louro, M. O., Cocho, J. A., Mera, A., Tutor, J. C., Immunochemical and enzymatic study of ceruloplasmin in rheumatoid arthritis. J. Trace Elem. Med. Biol. 2000, 14, 174-178.
55. Fox, P. L., Mukhopadhyay, C., Ehrenwald, E., Structure, oxidant activity, and cardiovascular mechanisms of human ceruloplasmin. Life Sci. 1995, 56, 1749-1758.